UNCOVERED: Rapeuticsmd - The Untold Story

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

TherapeuticsMD (NASDAQ:TXMD) brought in sales totaling $19.33 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 14.11%, resulting in a loss of $49.02 million.

TherapeuticsMD Inc (NASDAQ:TXMD) shares are trading higher after FDA approved the supplemental application, including minor revisions to Annovera's in vitro release testing specification that allowed for normal manufacturing variability. The FDA approved Annovera in August 2018 as the only long-lasting, reversible, procedure-free birth control. With the approval of the supplemental application, the company believes…

TherapeuticsMD (NASDAQ:TXMD) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings TherapeuticsMD missed estimated earnings by 18.0%, reporting an EPS of $-4.72 versus an estimate of $-4.0.

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

  TherapeuticsMD (NASDAQ:TXMD) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

TherapeuticsMD (NASDAQ:TXMD) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that TherapeuticsMD will report an earnings per share (EPS) of $-0.08.

TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million. VitaCare is a consumer-focused digital healthcare platform. TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023.  TXMD will also enter into a long-term services agreement to…

TherapeuticsMD Inc (NASDAQ: TXMD) is trading higher Monday after the company announced it would sell its prescription services business, vitaCare, to GoodRx Holdings Inc (NASDAQ: GDRX).